Grant Detail
The grant detail shows the name of the PI, active dates of the project, the funding institute and the abstract of the grant. This abstract is what is used to create the fingerprint of the grant. If any publications referencing this grant are found in the data, they will be listed here as well.
From Evidence-Base to Practice: Implementing RDAD in AAA Community-Based Services
1 April 2012 - 31 March 2017
NATIONAL INSTITUTE ON AGING
Total Funding: $ 455,712
DESCRIPTION (provided by applicant): This proposal responds to PA-11-123: Translational Research to Help Older Adults Maintain their Health and Independence in the Community. It is a translational investigation of RDAD (Reducing Disabilities in Alzheimer's Disease), an evidence-based program (published in JAMA and recommended for dissemination by the U.S. Administration on Aging Evidence-Based Intervention Grants Program). RDAD has demonstrated efficacy in helping older adults with dementia maintain physical function and alter long term care placement. It is a practical and scalable program with clear potential for moving evidence-based science findings into practice. A well-established partnership of Area Agencies on Aging (AAAs) and interdisciplinary and multidisciplinary researchers will collaborate to investigate the translation, implementation, and effectiveness of RDAD administered by AAA staff within their communities. This investigation has the potential to significantly affect public health, improving health and independence of older adults with dementia and their caregivers. The successful completion of this project will move the field of translational science forward by involving community partners in each phase of study, using two well-regarded strategies for translational work (NIH Behavioral Change Consortium (BCC) and Reach, Efficacy/Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM)), and applying established process and outcome measures to evaluate effectiveness. Qualitative and quantitative data will address two primary research questions: 1) Can AAA partners successfully translate and implement RDAD, and 2) Is AAA implementation of RDAD effective in producing desired outcomes among agencies, providers, and older adults with dementia and their family members. Adults age 65 and older with dementia and their family caregivers (240 dyads) will be enrolled in RDAD in both urban and rural AAAs in Oregon and Washington. A staggered time series design with repeated measures will be employed, with AAAs randomized for the time of implementation. Primary outcomes include care-recipient physical activity, functional status, and residential status;secondary outcomes include care-recipient and caregiver health, mood, and quality of life, care-recipient behavior, and caregiver perceived stress. Specific aims are to evaluate: 1) the translation and implementation of RDAD by AAAs;2) RDAD effectiveness on outcomes of physical health and independence among older adults with dementia and their family caregivers;and 3) RDAD outcomes of interest to community partners, including satisfaction with the program among those involved at each level (participant, provider, and agency), program delivery costs, and associated health care costs. Hypotheses are:1) AAAs will successfully implement RDAD;2) Participants (care-recipients and caregivers) will have significantly better outcomes following intervention as compared to baseline;and 3) Participants, providers, and AAAs will report satisfaction with RDAD;program delivery costs will be comparable to other AAA caregiver programs;and participant health care cost-streams will be reduced following implementation. 1 PUBLIC HEALTH RELEVANCE: This is a translational investigation of RDAD (Reducing Disabilities in Alzheimer's Disease), an evidence-based program with demonstrated efficacy in helping older adults with dementia maintain physical function and remain physically and mentally healthy. A well-established partnership of Area Agencies on Aging (AAAs) and an experienced group of multidisciplinary researchers from the University of Washington will collaborate to investigate the systematic translation, implementation, and effectiveness of RDAD as administered by AAA staff within the community. This investigation has the potential to significantly improve health and independence of older adults with dementia and their caregivers, and to move the field of translational science forward by addressing two primary research questions: 1) Can AAA partners successfully translate and implement RDAD, and 2) Is AAA implementation of RDAD effective in producing desired outcomes among agencies, providers, and older adults with dementia and their family members. 1
Scientific Context
This section shows information that has been computed by using the fingerprint of the grant, including related publications, related experts and related grants - all with fingerprints representing significant amounts of overlap between their fingerprint and this grant. The red dots indicate whether those experts or terms actually appear within this grant, showing potential and actual connections.
Related Grants
-
1.
KAYE, JEFFREY A
Oregon Roybal Center for Translational Research on Aging
30 September 2004 - 31 August 2014
NATIONAL INSTITUTE ON AGING
Total Funding: $ 2,902,264
-
2.
KAYE, JEFFREY A
Oregon Alzheimer's Disease Center
1 January 1997 - 31 March 2015
NATIONAL INSTITUTE ON AGING
Total Funding: $ 19,294,037
-
3.
STERN, YAAKOV
Predictors of Severity in Alzheimer's Disease
1 February 1989 - 31 August 2016
NATIONAL INSTITUTE ON AGING
Total Funding: $ 13,836,461
Related Publications
-
1.
1995M Grafström; B Winblad
Family burden in the care of the demented and nondemented elderly--a longitudinal study.
Alzheimer disease and associated disorders 1995;9(2):78-86. -
2.
2012Linda Teri; Glenise McKenzie; Rebecca G Logsdon; Susan M McCurry; Salli Bollin; Jennifer Mead; Heather Menne
The Gerontologist 2012;52(4):452-9. -
3.
2002Frances B Garfield; Denis Getsios; J Jaime Caro; Anders Wimo; Bengt Winblad
Assessment of Health Economics in Alzheimer's Disease (AHEAD): treatment with galantamine in Sweden.
PharmacoEconomics 2002;20(9):629-37.
Appears in this Publication







